Glp-1/gdf15 dual agonist to treat obesity and hyperglycaemia in mice and non-human primates

被引：0
|
作者：
Zhang, Y. Y. [1 ]
Kharitonenkov, A. [1 ]
Zhao, X. Y. [1 ]
Dong, X. N. [1 ]
Zhang, Y. Y. [1 ]
Zou, H. X. [1 ]
Jin, Y. G. [1 ]
Guo, W. [1 ]
Zhai, P. [1 ]
Chen, X. [1 ]
机构：
[1] Beijing QL Biopharmaceut Co Ltd, Beijing, Peoples R China
来源：
DIABETOLOGIA | 2022年 / 65卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
198
引用
收藏
页码：S103 / S104
页数：2
相关论文
共 50 条
  • [31] A dual GLP-1 and Gcg receptor agonist rescues spatial memory and synaptic plasticity in APP/PS1 transgenic mice
    Wang, Zhao-Jun
    Han, Yu-Fei
    Zhao, Fang
    Yang, Guang-Zhao
    Yuan, Li
    Cai, Hong-Yan
    Yang, Jun-Ting
    Holscher, Christian
    Qi, Jin-Shun
    Wu, Mei-Na
    HORMONES AND BEHAVIOR, 2020, 118
  • [32] A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP-1 dual agonist
    Bosch, Rolien
    Petrone, Marcella
    Arends, Rosalin
    Vicini, Paolo
    Sijbrands, Eric J. G.
    Hoefman, Sven
    Snelder, Nelleke
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2022, 11 (03): : 302 - 317
  • [33] New GLP-1 agonist dulaglutide improves metabolic dysfunction and extenuates development of non-acoholic steatohepatitis in mice
    Hupa, K. L.
    Hardtke-Wolenski, M.
    Manns, M. P.
    Jaeckel, E.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S432 - S433
  • [34] A Novel GLP-1/GIP Dual Agonist Normalizes Glucose Tolerance and Fat Mass in Diet Induced Obese Mice.
    Perez-Tilve, D.
    Tao, M.
    Ottaway, N.
    Pfluger, P.
    Hembree, J.
    Holland, J.
    Habegger, K.
    Mueller, T.
    Kirchner, H.
    Heppner, K.
    Gelfanov, V.
    Gidda, J.
    Zhang, L.
    DiMarchi, R.
    Tschoep, M.
    ENDOCRINE REVIEWS, 2010, 31 (03)
  • [35] Discovery and characterisation of HDM1005, a novel dual GLP-1 and GIP receptor agonist for the treatment of type 2 diabetes and obesity
    Jiang, C.
    Zhang, N.
    Teng, L.
    Guo, L.
    Pan, H.
    Zhang, Z.
    Dong, Z.
    Liu, D.
    DIABETOLOGIA, 2024, 67 : S338 - S338
  • [36] A novel GLP-1/FGF21 dual agonist ZT003 has therapeutic potential for obesity, MASH and SHTG
    Zhang, Y.
    Zhang, Y.
    Zhao, C.
    Lin, S.
    Guo, W.
    Wu, B.
    DIABETOLOGIA, 2024, 67 : S541 - S541
  • [37] Differential effect of a GLP-IR/GCGR dual agonist versus a single GLP-1R agonist in the activation of BAT and browning in diet indiced obesity in mice
    Ruis Canas, L.
    Valdecantos, P.
    Konkar, A.
    Dos Santos, A.
    Bednarek, M.
    Grimsby, J.
    Rondinone, C.
    Valverde, A. M.
    DIABETOLOGIA, 2016, 59 : S49 - S49
  • [38] HT-6184 Reverses Obesity Inflammation, Promotes Weight Loss With GLP-1 Agonist in High-Fat Diet Mice
    Bearss, David
    Bearss, Benjamin
    Avei, Taylor
    OBESITY, 2024, 32 : 19 - 19
  • [39] A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis
    Pan, Qi
    Lin, Shushan
    Li, Yu
    Liu, Liang
    Li, Xiaoping
    Gao, Xianglei
    Yan, Jiangyu
    Gu, Baohua
    Chen, Xiaofeng
    Li, Wenjia
    Tang, Xinfa
    Chen, Chao
    Guo, Lixin
    EBIOMEDICINE, 2021, 63
  • [40] MEDI0382 a novel GLP1/glucagon co-agonist induces profound body weight loss and improves metabolism in rodents and non-human primates
    Konkar, A.
    Ambery, P.
    Bednarek, M.
    Fritsch-Fredin, M.
    Grimsby, J.
    Henderson, S.
    Hornigold, D.
    Jackson, R.
    Rondinone, C.
    Trevaskis, J.
    Jermutus, L.
    DIABETOLOGIA, 2015, 58 : S310 - S310
12345